- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00265109
Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder
Open-Label Study of Levetiracetam in Body Dysmorphic Disorder
Study Overview
Detailed Description
Body dysmorphic disorder (BDD), a perceived defect in appearance (e.g., a "large" nose or facial "scarring"), is a relatively common disorder that causes marked distress and impairment in functioning. Recent data suggests that adults with BDD may respond to serotonin reuptake inhibitors (SRIs); however, response to SRIs is often only partial. About one third of patients do not respond to an SRI. Furthermore, patients may stop taking SRIs because of side effects (e.g., sexual side effects). For these reasons, additional monotherapy and SRI augmentation strategies are greatly needed.
Levetiracetam is primarily used as an antiseizure medication and has a wider safety margin than other antiepileptics. Preliminary scientific studies may suggest that it may be helpful for certain psychiatric symptoms and disorders. In the present study we propose to obtain pilot data on 1) levetiracetam monotherapy and 2) levetiracetam augmentation of SRIs in patients with BDD.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Rhode Island Hospital Body Dysmorphic Disorder Program
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women age 18-65;
- Current DSM-IV BDD or its delusional variant (delusional disorder, somatic type) for at least 3 months;
- A minimum total score of 20 on the Yale-Brown Obsessive Compulsive Scale Modified for BDD (BDD-YBOCS) (19);
- Suitable for treatment in an outpatient setting
Exclusion Criteria:
- Unstable medical illness, including renal failure or dialysis;
- Myocardial infarction within 6 months;
- Current pregnancy or lactation, or inadequate contraception in women of childbearing potential;
- A need for prn benzodiazepines, another antiepileptic medication, or an anticipated change in the dose of any concomitant medications while receiving treatment with levetiracetam;
- Clinically significant suicidality, including a suicide attempt within the past two months;
- Lifetime history of DSM-IV dementia, schizophrenia, or any other DSM-IV psychotic disorder that is not attributable to BDD;
- Current or recent (past 3 months) DSM-IV substance abuse or dependence;
- Initiation of ongoing psychotherapy from a mental health professional within 3 months prior to study baseline;
- Ongoing cognitive-behavioral therapy from a mental health professional;
- Previous treatment with levetiracetam;
- Treatment with investigational medication, depot neuroleptics, or ECT within the past 3 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: open label
Open-label trial; all participants received levetiracetam
|
The initial levetiracetam dose will be 250 mg/day, which will be increased to 250 mg BID after 1 week.
The dose will then be increased by 500 mg/day each week (given in BID dosing) to a maximum of 3,000 mg/day.
The dose will be raised more slowly or the maximum dose will not be reached if response occurs at a lower dose or side effects are problematic.
Subjects who are unable to tolerate at least 500 mg a day of levetiracetam will be withdrawn from the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Responders on the Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS)
Time Frame: Baseline to end week 12
|
The BDD-YBOCS, a reliable and valid 12-item semi-structured clinician-administered scale assessed BDD severity during the past week.
38 items are rated from 0 (no symptoms) to 4 (extreme symptoms); range=0-48.
This scale assesses preoccupation with the perceived appearance defects, associated compulsive behaviors, insight, and avoidance.
A ≥30% decrease in total score indicated response.
|
Baseline to end week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Who Improved on the Body Dysmorphic Disorder Clinical Global Impressions Scale - Clinician Rating for BDD Symptoms
Time Frame: Last week of treatment (week 12) or last week of treatment for early dropouts
|
The Clinical Global Improvement Scale (CGI) is a widely used 7-point scale that assesses global improvement or worsening of symptoms, with ratings ranging from "very much worse" (score of 7) to "very much improved" (score 1).
Ratings of much improved (score of 2) or very much improved (score of 1) defined improvement in BDD.
|
Last week of treatment (week 12) or last week of treatment for early dropouts
|
Percentage of Subjects Who Improved on the Clinical Global Improvement Scale (CGI) -- Clinician Rating of Global Improvement.
Time Frame: Last week of treatment (week 12)
|
The CGI is a widely used 7-point scale that assesses global improvement or worsening of symptoms, with ratings ranging from "very much worse" (score of 7) to "very much improved" (score 1).
Ratings of much improved (score of 2) or very much improved (score of 1) defined global improvement.
|
Last week of treatment (week 12)
|
Percentage of Participants Who Improved on the Body Dysmorphic Disorder Clinical Global Impressions Scale - Patient Rating for BDD Symptoms
Time Frame: Last week of treatment (week 12) or last week of treatment for early dropouts
|
The Clinical Global Improvement Scale (CGI) is a widely used 7-point scale that assesses global improvement or worsening of symptoms, with ratings ranging from "very much worse" (score of 7) to "very much improved" (score 1).
Ratings of much improved (score of 2) or very much improved (score of 1) defined improvement in BDD.
|
Last week of treatment (week 12) or last week of treatment for early dropouts
|
Percentage of Subjects Who Improved on the Clinical Global Improvement Scale (CGI) -- Patient Rating of Global Improvement.
Time Frame: Last week of treatment (week 12)
|
The CGI is a widely used 7-point scale that assesses global improvement or worsening of symptoms, with ratings ranging from "very much worse" (score of 7) to "very much improved" (score 1).
Ratings of much improved (score of 2) or very much improved (score of 1) defined global improvement.
|
Last week of treatment (week 12)
|
Scores on Brown Assessment of Beliefs Scale
Time Frame: Pre- and post-treatment (week 12)
|
The Brown Assessment of Beliefs Scale (BABS) is a 7-item semi-structured clinician-administered scale that assesses seven components of delusionality (insight) during the past week.
Scores range from 0-24, with higher scores indicating greater delusionality.
Beliefs are also categorized as delusional or nondelusional using an empirically derived cutpoint.
|
Pre- and post-treatment (week 12)
|
Scores on Clinical Global Severity
Time Frame: Pre- and post-treatment (week 12)
|
The 7-point Clinical Global Severity Scale assessed current illness severity at study baseline (score of 1=normal, not at all ill, and score of 7=among the most extremely ill patients).
|
Pre- and post-treatment (week 12)
|
Scores on Hamilton Depression Rating Scale
Time Frame: Pre- and post-treatment (week 12)
|
The 24-item Hamilton Rating Scale for Depression (HAM-D 24) is a widely used reliable and valid clinician-administered measure of current severity of depressive symptoms.
Scores range from 0 to 76, with higher scores reflecting more severe depressive symptoms.
|
Pre- and post-treatment (week 12)
|
Scores on Beck Anxiety Inventory
Time Frame: Pre- and post-treatment (week 12)
|
The Beck Anxiety Inventory (BAI) is a reliable, valid, and widely used 21-item self-report measure of anxiety during the past week which focuses on somatic symptoms.44
The BAI has been shown to be sensitive to change.
Scores range from 0-63, with higher scores reflecting more severe symptoms.
|
Pre- and post-treatment (week 12)
|
Scores on Social Phobia Inventory
Time Frame: Pre- and post-treatment (week 12)
|
The Social Phobia Inventory (SPIN) is a 17-item self-report questionnaire that assesses fear, avoidance, and physiological arousal associated with social anxiety during the past week.
This scale is reliable, valid, and sensitive to change.
Scores range from 0-68, with a score ≥19 distinguishing patients with social phobia from both healthy controls and psychiatric controls without social phobia.
|
Pre- and post-treatment (week 12)
|
Scores on Global Assessment of Functioning
Time Frame: Pre- and post-treatment (week 12)
|
The Global Assessment of Functioning (GAF) is a global measure of symptom severity and psychological, social, and occupational functioning.
Scores range from 0-100, with lower scores denoting more severe illness and/or poorer functioning
|
Pre- and post-treatment (week 12)
|
Scores on Social and Occupational Functioning Scale (SOFAS)
Time Frame: Pre- and post-treatment (week 12)
|
The Social and Occupational Functioning Scale (SOFAS) is a global measure of psychological, social, and occupational functioning.
Scores range from 0-100, with lower scores denoting more severe illness and/or poorer functioning
|
Pre- and post-treatment (week 12)
|
Scores on The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) -- Short Form
Time Frame: Pre- and post-treatment (week 12)
|
The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), Short Form, is a 14-item reliable and valid measure that is sensitive to change.
Transformed scores range from 0 from 100, with lower scores reflecting poorer quality of life.The Short Form transformed score is reported.
|
Pre- and post-treatment (week 12)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Katharine A Phillips, M.D., Rhode Island Hospital/ Brown University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0410-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Body Dysmorphic Disorder
-
Karolinska InstitutetCompletedBody Dysmorhpic DisorderSweden
-
Karolinska InstitutetVastra Gotaland Region; Region Skane; Region StockholmRecruitingBody Dysmorphic DisordersSweden
-
Massachusetts General HospitalTelefónica S.A.CompletedBody Dysmorphic DisordersUnited States
-
Icahn School of Medicine at Mount SinaiTerminated
-
Institute of Psychiatry, LondonCompletedBody Dysmorphic DisorderUnited Kingdom
-
Massachusetts General HospitalCompleted
-
Westwood Institute for Anxiety Disorders, IncUnknownBody Dysmorphic DisordersUnited States
-
Centre for Addiction and Mental HealthUniversity Health Network, TorontoRecruiting
-
Koa Health B.V.Massachusetts General HospitalActive, not recruitingBody Dysmorphic DisordersUnited States
-
Florida State UniversityCompletedBody Dysmorphic DisorderUnited States
Clinical Trials on Levetiracetam
-
Johns Hopkins UniversityNational Institute on Aging (NIA)CompletedMild Cognitive Impairment (MCI)United States
-
UCB Pharma SACompleted
-
Odense University HospitalCompleted
-
Richard H. HaasThrasher Research FundCompletedSeizures | Disorder of Fetus or NewbornUnited States
-
UCB Japan Co. Ltd.CompletedEpilepsies, PartialJapan
-
Odense University HospitalCompleted
-
Oslo University HospitalUnknownSubclinical Sleep-Activated Epileptiform Activity | CSWSNorway
-
National Institute of Mental Health (NIMH)CompletedBipolar DisorderUnited States
-
Odense University HospitalCompleted
-
UCB PharmaParexelCompletedHealthy Subjects | Renal ImpairmentsJapan